Skip to content
WorldBrand.AI

ArtemiFlow controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2020

    Controversy over possible COVID-19 use of artemisinin

    Discussion of artemisinin as a possible COVID-19 treatment attracted criticism because of questions about supporting evidence and possible conflicts of interest related to Peter Seeberger's leadership of ArtemiFlow and ArtemiLife. The supplied reference records critical reporting in Süddeutsche Zeitung and a subsequent response in Focus, without documenting a regulatory or judicial determination.

    Source